NASDAQ:DAWN Day One Biopharmaceuticals (DAWN) Stock Price, News & Analysis → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free DAWN Stock Alerts $15.47 +0.09 (+0.59%) (As of 10:04 AM ET) Add Compare Share Share Today's Range$15.18▼$15.7050-Day Range$13.77▼$17.4652-Week Range$9.67▼$17.85Volume102,475 shsAverage Volume638,085 shsMarket Capitalization$1.35 billionP/E RatioN/ADividend YieldN/APrice Target$39.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Day One Biopharmaceuticals alerts: Email Address Day One Biopharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.63 Rating ScoreUpside/Downside157.5% Upside$39.83 Price TargetShort InterestBearish15.24% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.76Based on 18 Articles This WeekInsider TradingSelling Shares$883,160 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.66) to ($2.12) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.15 out of 5 starsMedical Sector535th out of 910 stocksPharmaceutical Preparations Industry242nd out of 426 stocks 3.3 Analyst's Opinion Consensus RatingDay One Biopharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on 6 buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageDay One Biopharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted15.24% of the float of Day One Biopharmaceuticals has been sold short.Short Interest Ratio / Days to CoverDay One Biopharmaceuticals has a short interest ratio ("days to cover") of 14.5, which indicates bearish sentiment.Change versus previous monthShort interest in Day One Biopharmaceuticals has recently decreased by 6.56%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldDay One Biopharmaceuticals does not currently pay a dividend.Dividend GrowthDay One Biopharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DAWN. Previous Next 2.6 News and Social Media Coverage News SentimentDay One Biopharmaceuticals has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Day One Biopharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for DAWN on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Day One Biopharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -88% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Day One Biopharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $883,160.00 in company stock.Percentage Held by InsidersOnly 8.40% of the stock of Day One Biopharmaceuticals is held by insiders.Percentage Held by Institutions87.95% of the stock of Day One Biopharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Day One Biopharmaceuticals are expected to grow in the coming year, from ($2.66) to ($2.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Day One Biopharmaceuticals is -6.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Day One Biopharmaceuticals is -6.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDay One Biopharmaceuticals has a P/B Ratio of 3.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressBitcoin Rockets To Record High But Buy THIS InsteadRecently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…>>Click here to find out what it is. About Day One Biopharmaceuticals Stock (NASDAQ:DAWN)Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.Read More DAWN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DAWN Stock News HeadlinesApril 23, 2024 | insidertrades.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Samuel C. Blackman Sells 10,000 SharesApril 23, 2024 | americanbankingnews.comDay One Biopharmaceuticals (NASDAQ:DAWN) Price Target Increased to $36.00 by Analysts at JPMorgan Chase & Co.April 23, 2024 | Paradigm Press (Ad)Bitcoin Rockets To Record High But Buy THIS InsteadRecently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…April 23, 2024 | americanbankingnews.comDay One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Up After Analyst UpgradeApril 22, 2024 | markets.businessinsider.comBuy Rating Affirmed for Day One Biopharmaceuticals on Strong Tovorafenib Prospects and Market ImpactApril 21, 2024 | americanbankingnews.comDay One Biopharmaceuticals (NASDAQ:DAWN) Trading Down 4.7%April 18, 2024 | americanbankingnews.comShort Interest in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Declines By 6.6%April 17, 2024 | americanbankingnews.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Consensus Rating of "Moderate Buy" by BrokeragesApril 23, 2024 | Paradigm Press (Ad)Bitcoin Rockets To Record High But Buy THIS InsteadRecently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…April 16, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: OptimizeRx (OPRX), Day One Biopharmaceuticals (DAWN)April 10, 2024 | markets.businessinsider.comBuy Rating on Day One Biopharmaceuticals Ahead of Tovorafenib PDUFA Date and Potential for Market DisruptionApril 4, 2024 | morningstar.comDay One Biopharmaceuticals Inc DAWNMarch 26, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Day One Biopharmaceuticals (DAWN), BioMarin Pharmaceutical (BMRN) and Argenx Se (ARGX)March 17, 2024 | finance.yahoo.comDAWN Jul 2024 17.500 callMarch 15, 2024 | finance.yahoo.comCompanies Like Day One Biopharmaceuticals (NASDAQ:DAWN) Are In A Position To Invest In GrowthFebruary 29, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Day One Biopharmaceuticals (DAWN), Crinetics Pharmaceuticals (CRNX)February 28, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Day One Biopharmaceuticals Amid Tovorafenib’s Promising Prospects and Financial StabilityFebruary 28, 2024 | finance.yahoo.comDay One Biopharmaceuticals Inc (DAWN) Reports Q4 and Full Year 2023 Financial ResultsFebruary 27, 2024 | finanznachrichten.deDay One Biopharmaceuticals, Inc.: Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate ProgressFebruary 27, 2024 | edition.cnn.comDay One Biopharmaceuticals, Inc.February 26, 2024 | globenewswire.comDay One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate ProgressFebruary 6, 2024 | benzinga.comDay One Biopharmaceutical Stock (NASDAQ:DAWN), Short Interest ReportFebruary 1, 2024 | seekingalpha.comNavigating Day One Biopharmaceuticals' Financial Health And Clinical ProspectsDecember 19, 2023 | finance.yahoo.comDay One to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNovember 27, 2023 | finance.yahoo.comMilei to Send ‘Shock’ Package to Argentina’s Congress on Day OneNovember 14, 2023 | finance.yahoo.comDay One to Participate in the Piper Sandler 35th Annual Healthcare ConferenceNovember 9, 2023 | morningstar.comDay One Biopharmaceuticals IncSee More Headlines Receive DAWN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Day One Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/26/2024Today4/23/2024Next Earnings (Estimated)5/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:DAWN CUSIPN/A CIK1845337 Webdayonebio.com Phone650-484-0899FaxN/AEmployees155Year FoundedN/APrice Target and Rating Average Stock Price Target$39.83 High Stock Price Target$50.00 Low Stock Price Target$34.00 Potential Upside/Downside+159.0%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-188,920,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-51.67% Return on Assets-48.30% Debt Debt-to-Equity RatioN/A Current Ratio12.72 Quick Ratio12.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.98 per share Price / Book3.86Miscellaneous Outstanding Shares87,380,000Free Float80,037,000Market Cap$1.34 billion OptionableOptionable Beta-1.48 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Jeremy Bender M.B.A. (Age 53)Ph.D., CEO, President & Director Comp: $900kDr. Samuel C. Blackman M.D. (Age 55)Ph.D., Co-Founder and Head of R&D Comp: $651kMr. Charles N. York II (Age 47)COO, CFO & Secretary Comp: $715kDr. Mike Preigh Ph.D.Chief of Technology OperationsMr. Adam Dubow (Age 57)General Counsel Ms. Jaa RobersonChief People OfficerDr. Davy Chiodin Ph.D.Pharm.D., Chief Development OfficerMs. Lauren Merendino M.B.A. (Age 48)Chief Commercial Officer Dr. Elly Barry M.D.Chief Medical OfficerMore ExecutivesKey CompetitorsPacira BioSciencesNASDAQ:PCRXVerona PharmaNASDAQ:VRNAIronwood PharmaceuticalsNASDAQ:IRWDKiniksa PharmaceuticalsNASDAQ:KNSADeciphera PharmaceuticalsNASDAQ:DCPHView All CompetitorsInsiders & InstitutionsSamuel C BlackmanSold 10,000 sharesTotal: $160,200.00 ($16.02/share)Hennion & Walsh Asset Management Inc.Bought 1,445 shares on 4/17/2024Ownership: 0.068%Samuel C BlackmanSold 10,000 sharesTotal: $160,100.00 ($16.01/share)Wellington Management Group LLPBought 91,393 shares on 3/5/2024Ownership: 0.239%Fisher Asset Management LLCBought 32,238 shares on 3/5/2024Ownership: 0.078%View All Insider TransactionsView All Institutional Transactions DAWN Stock Analysis - Frequently Asked Questions Should I buy or sell Day One Biopharmaceuticals stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Day One Biopharmaceuticals in the last twelve months. There are currently 1 sell rating, 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" DAWN shares. View DAWN analyst ratings or view top-rated stocks. What is Day One Biopharmaceuticals' stock price target for 2024? 8 brokers have issued twelve-month target prices for Day One Biopharmaceuticals' stock. Their DAWN share price targets range from $34.00 to $50.00. On average, they anticipate the company's share price to reach $39.83 in the next year. This suggests a possible upside of 157.5% from the stock's current price. View analysts price targets for DAWN or view top-rated stocks among Wall Street analysts. How have DAWN shares performed in 2024? Day One Biopharmaceuticals' stock was trading at $14.60 at the beginning of the year. Since then, DAWN stock has increased by 6.0% and is now trading at $15.47. View the best growth stocks for 2024 here. Are investors shorting Day One Biopharmaceuticals? Day One Biopharmaceuticals saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 8,980,000 shares, a decline of 6.6% from the March 15th total of 9,610,000 shares. Based on an average trading volume of 619,200 shares, the days-to-cover ratio is presently 14.5 days. Currently, 15.2% of the company's stock are short sold. View Day One Biopharmaceuticals' Short Interest. When is Day One Biopharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024. View our DAWN earnings forecast. How were Day One Biopharmaceuticals' earnings last quarter? Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) issued its quarterly earnings results on Monday, February, 26th. The company reported ($0.64) EPS for the quarter, missing analysts' consensus estimates of ($0.57) by $0.07. What ETFs hold Day One Biopharmaceuticals' stock? ETFs with the largest weight of Day One Biopharmaceuticals (NASDAQ:DAWN) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Tema Oncology ETF (CANC), Range Cancer Therapeutics ETF (CNCR) and Loncar China Biopharma ETF (CHNA).ALPS Medical Breakthroughs ETF (SBIO). When did Day One Biopharmaceuticals IPO? Day One Biopharmaceuticals (DAWN) raised $126 million in an initial public offering (IPO) on Thursday, May 27th 2021. The company issued 8,400,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Piper Sandler served as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Day One Biopharmaceuticals' major shareholders? Day One Biopharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.07%). Insiders that own company stock include Adam Dubow, Ai Day1 Llc, Charles N York II, Jeremy Bender, Julie Papanek Grant, Michael Gladstone, Papanek Julie Grant, Pharmaceutical Co Ltd Takeda, Samuel C Blackman, Venture Fund Xi LP Atlas and Xi LP Canaan. View institutional ownership trends. How do I buy shares of Day One Biopharmaceuticals? Shares of DAWN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DAWN) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishingtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Day One Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
